2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1740

Effectiveness and Safety of Tocilizumab for the Treatment of Refractory Systemic Sclerosis Associated Interstitial Lung Disease: A Case Series
Abstract Number: 1741

Disease Duration and Autoantibodies Predict Distinct Skin Score Trajectories in Diffuse Cutaneous Systemic Sclerosis
Abstract Number: 1742

Disease-Specific Autoantibodies Associate with Remarkably Different Risk of Development of Significant Lung Fibrosis in Systemic Sclerosis
Abstract Number: 1743

Serum Markers Potentially Associated with PAH in Systemic Sclerosis; A Targeted Screening Approach
Abstract Number: 1744

Prognostic Value of Right Heart Involvement in Systemic Sclerosis:Not Only Pulmonary Arterial Hypertension
Abstract Number: 1745

Efficacy of Eosinophilic Granulomatosis with Polyangiitis (Churg–Strauss) Treatments According to the Type of Manifestations Based on Analysis of 376 Patients
Abstract Number: 1746

Impact of Interstitial Lung Disease on the Long-Term Survival in 76 Japanese Patients with Microscopic Polyangiitis
Abstract Number: 1747

Long-Term Outcomes of Patients with Nonsevere Eosinophilic Granulomatosis with Polyangiitis Given Azathioprine and Glucocorticoids for Remission Induction
Abstract Number: 1748

Interstitial Lung Disease in ANCA-Positive Vasculitis Patients
Abstract Number: 1749

Long-Term Renal Outcome in Pulmonary-Limited Microscopic Polyangiitis
Abstract Number: 1750

Rheumatoid Factor Titer Is Inversely Correlated with ANCA Titer and Relates to Characteristic Manifestations in Patients with Eosinophilic Granulomatosis with Polyangiitis
Abstract Number: 1751

Interstitial Lung Disease during ANCA-Associated Vasculitis: A Poor-Prognosis Factor
Abstract Number: 1752

Asthma in Eosinophilic Granulomatosis with Polyangiitis Treated with Rituximab
Abstract Number: 1753

Interstitial Lung Disease in ANCA-Associated Vasculitis Defines a Unique Subgroup of Patients at High Risk for Respiratory Death: A Cluster Analysis
Abstract Number: 1754

Clinical and Economic Characteristics of Patients Diagnosed with Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly Churg-Strauss Syndrome) in the United States

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].